Journal Article

Cefoxitin resistance as a surrogate marker for the detection of methicillin-resistant <i>Staphylococcus aureus</i>

Clarence J. Fernandes, Lorna A. Fernandes and Peter Collignon

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 55, issue 4, pages 506-510
Published in print April 2005 | ISSN: 0305-7453
Published online April 2005 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dki052
Cefoxitin resistance as a surrogate marker for the detection of methicillin-resistant Staphylococcus aureus

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care

GO

Show Summary Details

Preview

Objectives: To evaluate the usefulness of cefoxitin when used as a surrogate marker for the detection of methicillin resistance.

Patients and methods: Eight hundred and seventy-one strains of Staphylococcus aureus, collected from eight tertiary referral centres serving diverse socio-economic populations, were included in the study using NCCLS disc diffusion and the agar dilution methods.

Results: Using cefoxitin and NCCLS criteria for disc diffusion, the sensitivity and specificity for recognizing methicillin resistance were both 100%. Similar results were obtained when the strains were tested by the agar dilution method. The cefoxitin MICs for methicillin-susceptible strains were ≤ 4 mg/L.

Conclusions: Testing with cefoxitin as a surrogate marker for the detection of methicillin resistance was very accurate with both disc diffusion and agar dilution methods. Such testing clearly distinguished methicillin-resistant strains of S. aureus from methicillin-susceptible strains.

Keywords: community-onset MRSA infections; hospital-acquired infections; non-multiresistant Staphylococcus aureus; oxacillin resistance

Journal Article.  2918 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.